Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($2.77), $2.51 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $30.01 million versus the consensus estimate of $37.84 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.